His responsibilities in DRA’s operations are Market Access, Marketing Compliance and Medical Services, Pharmacovigilance and Language and Communications Services.
We want to promote actions that can effectively reduce environmental impact of pharmaceutical manufacturing and the different stages of medicinal product’s life cycle.
The content of released guidance document is envisaged to form the basis for common specifications to be adopted according to Article 9 of Regulation (EU) 2017/746 in the coming months.
The new regulation implements the obligations set out in medical device EU-regulations (2017/745 and 2017/746) and in national legislation 719/2021 in Finland.
To guide registration activities, EU-Commission has released a Questions and answers on obligations and related rules for the registration in EUDAMED of actors other than manufacturers, authorized representatives and importers subject to the obligations of Article 31 MDR and Article 28 IVDR in June.
These should be noted by Swiss medical device manufacturers and legal manufacturer with Swiss Notified body or Swiss-based Authorized Representative.
During this spring, many experienced experts and fresh top performers have joined our team. The team of Marketing supervision and Medical services has been complemented with two new top experts. Kati Mönkkönen, Ph.D., has years of experience in the pharmaceutical industry, e.g. from Sanquin and Biogen. Her experience especially covers medical assignments. Anna Hiltunen, who […]
Tiina Riihimäki, PhD (Medical Technology), has been appointed as Health Technology Team Leader at DRA.
When it comes to electronic product information, a central question is the patient’s digital health information literacy. At the moment, there is electronic product information available, but the challenge is how accessible and easy-to-find it is.
IMA has published a new guideline on the Zero Day MRP/RUP process (in Icelandic).
The charitable exercise day will take place on 19 May.